InvestorsHub Logo
Followers 66
Posts 11443
Boards Moderated 0
Alias Born 10/20/2009

Re: ECole post# 150500

Friday, 11/29/2013 8:51:10 AM

Friday, November 29, 2013 8:51:10 AM

Post# of 345725
Thanks for the article Ecole...other notable statements imho...

These are essentially unpartnered technologies and we have other partnering opportunities within our clinical and preclinical pipeline.



once again regarding Cotara..

Cotara which is also ready for Phase III in which we intend to initiate that Phase III study in conjunction with partnership.



We then target that exposed PS with the monoclonal antibody again which we call Bavituximab and that antibody exerts anti-tumor effects.



And in fact it's been shown in multiple studies, published results that high levels of MDSCs in cancer patients are directly associated with pro prognosis of those patients again because the can't activate their system.



wow and so much more...but IF all proven true(chuckle) we are on our way to greatness!!! imho

What is up with the grammar and spelling throughout that transcript anyway? sheesh....

wook

Best of Data, FDA Approval(s), Partner(s), Imaging, Production and Research!!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News